Form 4 for EXEL EXELIXIS, INC.
Accepted 2025-05-16 00:00:00 ET · period of report 2025-05-15 · accession 0000939767-25-000076 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-16 | 2025-05-16 | EXEL | Peterson Amy C. | CMO, EVP Prod Dev, Med Aff | S - Sale+OE | $45.47 | -72.8K | 465.4K | -14% | -$3.31M |
| D | 2025-05-16 | 2025-05-15 | EXEL | Peterson Amy C. | CMO, EVP Prod Dev, Med Aff | F - Tax | $44.65 | -8,303 | 498.2K | -2% | -$370.7K |
| D | 2025-05-16 | 2025-05-16 | EXEL | Peterson Amy C. | CMO, EVP Prod Dev, Med Aff | M - OptEx | $21.75 | +40.0K | 538.2K | +8% | +$870.0K |
| D | 2025-05-16 | 2025-05-16 | EXEL | Peterson Amy C. | CMO, EVP Prod Dev, Med Aff | M - OptEx | $0.00 | -40.0K | 120.0K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-16 | S | D | 72,776 | $45.47 | 465,393 | D | — | — | (F3) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $45.08 to $46.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. (F2) Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| 2 | Common | Common Stock | 2025-05-15 | F | D | 8,303 | $44.65 | 498,169 | D | — | — | (F1) Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded February 23, 2024. (F2) Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| 3 | Common | Common Stock | 2025-05-16 | M | A | 40,000 | $21.75 | 538,169 | D | — | — | (F2) Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| 4 | Derivative | Option (right to buy) | 2025-05-16 | M | D | 40,000 | $0.00 | 120,000 | D | $21.75 · 2024-08-24 to 2030-08-23 | 40,000 Common Stock | (F4) The option, representing the right to purchase a total of 160,000 shares of Common Stock, 40,000 shares became exercisable on August 24, 2024 and the remainder will become fully exercisable on August 24, 2027. |